82_FR_11509 82 FR 11474 - Center for Scientific Review; Notice of Closed Meetings

82 FR 11474 - Center for Scientific Review; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 35 (February 23, 2017)

Page Range11474-11475
FR Document2017-03528

Federal Register, Volume 82 Issue 35 (Thursday, February 23, 2017) 
[Federal Register Volume 82, Number 35 (Thursday, February 23, 2017)]
[Notices]
[Pages 11474-11475]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-03528]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: Neurodevelopmental and Other Neurological 
Disorders.
    Date: March 8, 2017.
    Time: 3:00 p.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Samuel C Edwards, Ph.D., IRG Chief, Center for 
Scientific Review, National Institutes of Health, 6701 Rockledge 
Drive, Room 5210, MSC 7846, Bethesda, MD 20892, (301) 435-1246, 
[email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.
    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Small Business: HIV/AIDS Innovative Research Applications.
    Date: March 15, 2017.
    Time: 1:00 p.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Virtual Meeting).
    Contact Person: Kenneth A Roebuck, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5106, MSC 7852, Bethesda, MD 
20892, (301) 435-1166, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Molecular and Cellular Mechanisms of Neurodegenerative 
Disease.
    Date: March 15, 2017.
    Time: 1:30 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Christine A Piggee, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 4186, MSC 7850, Bethesda, MD 
20892, 301-435-0657, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Imaging Guided Drug Delivery.
    Date: March 16, 2017.
    Time: 8:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 
8120 Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Chiayeng Wang, Ph.D., Scientific Review Officer, 
Center for Scientific Review, 6701 Rockledge Drive, Room 5213, MSC 
7852, Bethesda, MD 20892, 301-435-2397, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: Social and Behavioral Influences on HIV 
Prevention and Treatment.
    Date: March 17, 2017.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Virtual Meeting).
    Contact Person: Shalanda A Bynum, Ph.D., MPH, Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 3206, Bethesda, MD 20892, 301-
755-4355, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Small Business: Cell and Molecular Biology.
    Date: March 21-22, 2017.
    Time: 8:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 
8120 Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Amy Kathleen Wernimont, Ph.D., Scientific Review 
Officer, Center for Scientific Review, 6701 Rockledge Drive, 
Bethesda, MD 20892, 301-827-6427, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: Chemo/Dietary Prevention.
    Date: March 23, 2017.
    Time: 12:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Syed M Quadri, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 6210, MSC 7804, Bethesda, MD 20892, 301-435-
1211, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: Topics in Cell Biology.
    Date: March 23, 2017.
    Time: 12:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Janet M Larkin, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 1102, MSC 7840, Bethesda, MD 
20892, 301-806-2765, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; PAR Panel: Metabolic Reprogramming to Improve Immunotherapy.
    Date: March 23, 2017.
    Time: 12:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.

[[Page 11475]]

    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Syed M Quadri, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 6210, MSC 7804, Bethesda, MD 20892, 301-435-
1211, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: Emerging Technologies in Neuroscience.
    Date: March 24, 2017.
    Time: 10:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Virtual Meeting).
    Contact Person: Sharon S Low, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 5104, MSC 5104, Bethesda, MD 20892-5104, 301-
237-1487, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: February 17, 2017.
Anna Snouffer,
 Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-03528 Filed 2-22-17; 8:45 am]
 BILLING CODE 4140-01-P

11474 Federal Register / Vol. 82, No. 35 / Thursday, February 23, 2017 / Notices The meeting will be closed to the property such as patentable material, Room 5213, MSC 7852, Bethesda, MD 20892, public in accordance with the and personal information concerning 301–435–2397, chiayeng.wang@nih.gov. provisions set forth in sections individuals associated with the grant Name of Committee: Center for Scientific 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., applications, the disclosure of which Review Special Emphasis Panel; Member as amended. The grant applications and would constitute a clearly unwarranted Conflict: Social and Behavioral Influences on the discussions could disclose invasion of personal privacy. HIV Prevention and Treatment. Date: March 17, 2017. confidential trade secrets or commercial Name of Committee: Center for Scientific Time: 10:00 a.m. to 5:00 p.m. property such as patentable material, Review Special Emphasis Panel; Member Agenda: To review and evaluate grant and personal information concerning Conflict: Neurodevelopmental and Other applications. individuals associated with the grant Neurological Disorders. Place: National Institutes of Health, 6701 applications, the disclosure of which Date: March 8, 2017. Rockledge Drive, Bethesda, MD 20892, would constitute a clearly unwarranted Time: 3:00 p.m. to 6:00 p.m. (Virtual Meeting). invasion of personal privacy. Agenda: To review and evaluate grant Contact Person: Shalanda A Bynum, Ph.D., applications. MPH, Scientific Review Officer, Center for Name of Committee: National Institute of Place: National Institutes of Health, 6701 Scientific Review, National Institutes of Environmental Health Sciences Special Rockledge Drive, Bethesda, MD 20892, Emphasis Panel, Review of time-sensitive Health, 6701 Rockledge Drive, Room 3206, (Telephone Conference Call). Bethesda, MD 20892, 301–755–4355, R21’s. Contact Person: Samuel C Edwards, Ph.D., Date: March 10, 2017. bynumsa@csr.nih.gov. IRG Chief, Center for Scientific Review, Time: 11:00 a.m. to 2:00 p.m. Name of Committee: Center for Scientific National Institutes of Health, 6701 Rockledge Agenda: To review and evaluate grant Review Special Emphasis Panel; Small Drive, Room 5210, MSC 7846, Bethesda, MD applications. 20892, (301) 435–1246, edwardss@ Business: Cell and Molecular Biology. Place: NIEHS/National Institutes of Health, csr.nih.gov. Date: March 21–22, 2017. Keystone Building, 530 Davis Drive, Room Time: 8:00 a.m. to 6:00 p.m. 3003, Research Triangle Park, NC 27709, This notice is being published less than 15 Agenda: To review and evaluate grant (Telephone Conference Call). days prior to the meeting due to the timing applications. Contact Person: Laura A. Thomas, limitations imposed by the review and Place: Doubletree Hotel Bethesda, Scientific Review Officer, Scientific Review funding cycle. (Formerly Holiday Inn Select), 8120 Branch, Division of Extramural Research and Name of Committee: Center for Scientific Wisconsin Avenue, Bethesda, MD 20814. Training, National Institute of Environmental Review Special Emphasis Panel; Small Contact Person: Amy Kathleen Wernimont, Health Sciences, Research Triangle Park, NC Business: HIV/AIDS Innovative Research Ph.D., Scientific Review Officer, Center for 27709, 919–541–2824, laura.thomas@ Applications. Scientific Review, 6701 Rockledge Drive, nih.gov. Date: March 15, 2017. Bethesda, MD 20892, 301–827–6427, (Catalogue of Federal Domestic Assistance Time: 1:00 p.m. to 6:00 p.m. amy.wernimont@nih.gov. Program Nos. 93.115, Biometry and Risk Agenda: To review and evaluate grant applications. Name of Committee: Center for Scientific Estimation—Health Risks from Review Special Emphasis Panel; Member Environmental Exposures; 93.142, NIEHS Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, Conflict: Chemo/Dietary Prevention. Hazardous Waste Worker Health and Safety (Virtual Meeting). Date: March 23, 2017. Training; 93.143, NIEHS Superfund Contact Person: Kenneth A Roebuck, Ph.D., Time: 12:00 p.m. to 3:00 p.m. Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Scientific Review Officer, Center for Agenda: To review and evaluate grant Development in the Environmental Health Scientific Review, National Institutes of applications. Sciences; 93.113, Biological Response to Health, 6701 Rockledge Drive, Room 5106, Place: National Institutes of Health, 6701 Environmental Health Hazards; 93.114, MSC 7852, Bethesda, MD 20892, (301) 435– Rockledge Drive, Bethesda, MD 20892, Applied Toxicological Research and Testing, 1166, roebuckk@csr.nih.gov. (Telephone Conference Call). National Institutes of Health, HHS) Name of Committee: Center for Scientific Contact Person: Syed M Quadri, Ph.D., Review Special Emphasis Panel; Molecular Scientific Review Officer, Center for Dated: February 17, 2017. Scientific Review, National Institutes of and Cellular Mechanisms of Natasha M. Copeland, Health, 6701 Rockledge Drive, Room 6210, Neurodegenerative Disease. Program Analyst, Office of Federal Advisory Date: March 15, 2017. MSC 7804, Bethesda, MD 20892, 301–435– Committee Policy. Time: 1:30 p.m. to 4:00 p.m. 1211, quadris@csr.nih.gov. [FR Doc. 2017–03530 Filed 2–22–17; 8:45 am] Agenda: To review and evaluate grant Name of Committee: Center for Scientific BILLING CODE 4140–01–P applications. Review Special Emphasis Panel; Member Place: National Institutes of Health, 6701 Conflict: Topics in Cell Biology. Rockledge Drive, Bethesda, MD 20892, Date: March 23, 2017. DEPARTMENT OF HEALTH AND (Telephone Conference Call). Time: 12:00 p.m. to 5:00 p.m. Contact Person: Christine A Piggee, Ph.D., Agenda: To review and evaluate grant HUMAN SERVICES Scientific Review Officer, Center for applications. Scientific Review, National Institutes of Place: National Institutes of Health, 6701 National Institutes of Health Health, 6701 Rockledge Drive, Room 4186, Rockledge Drive, Bethesda, MD 20892, Center for Scientific Review; Notice of MSC 7850, Bethesda, MD 20892, 301–435– (Telephone Conference Call). 0657, christine.piggee@nih.gov. Contact Person: Janet M Larkin, Ph.D., Closed Meetings Scientific Review Officer, Center for Name of Committee: Center for Scientific Pursuant to section 10(d) of the Review Special Emphasis Panel; Imaging Scientific Review, National Institutes of Federal Advisory Committee Act, as Guided Drug Delivery. Health, 6701 Rockledge Drive, Room 1102, Date: March 16, 2017. MSC 7840, Bethesda, MD 20892, 301–806– amended (5 U.S.C. App.), notice is Time: 8:00 a.m. to 6:00 p.m. 2765, larkinja@csr.nih.gov. hereby given of the following meetings. rmajette on DSK2TPTVN1PROD with NOTICES The meetings will be closed to the Agenda: To review and evaluate grant Name of Committee: Center for Scientific applications. Review Special Emphasis Panel; PAR Panel: public in accordance with the Place: Doubletree Hotel Bethesda, Metabolic Reprogramming to Improve provisions set forth in sections (Formerly Holiday Inn Select), 8120 Immunotherapy. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Wisconsin Avenue, Bethesda, MD 20814. Date: March 23, 2017. as amended. The grant applications and Contact Person: Chiayeng Wang, Ph.D., Time: 12:00 p.m. to 4:00 p.m. the discussions could disclose Scientific Review Officer, Center for Agenda: To review and evaluate grant confidential trade secrets or commercial Scientific Review, 6701 Rockledge Drive, applications. VerDate Sep<11>2014 14:10 Feb 22, 2017 Jkt 241001 PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 E:\FR\FM\23FEN1.SGM 23FEN1

Federal Register / Vol. 82, No. 35 / Thursday, February 23, 2017 / Notices 11475 Place: National Institutes of Health, 6701 301–496–2644. A signed Confidential alters signaling to drive cytokine Rockledge Drive, Bethesda, MD 20892, Disclosure Agreement will be required responses that enhance septic shock.’’ (Telephone Conference Call). to receive copies of unpublished patent Immunity 44.6 (2016): 1365–1378. Contact Person: Syed M Quadri, Ph.D., Scientific Review Officer, Center for applications. Intellectual Property: HHS Reference Scientific Review, National Institutes of SUPPLEMENTARY INFORMATION: No. E–112–2016/0—U.S. Patent Health, 6701 Rockledge Drive, Room 6210, Technology description follows. Application No. 62/308,144 filed 03/14/ MSC 7804, Bethesda, MD 20892, 301–435– 2016. 1211, quadris@csr.nih.gov. CD300b Expression Exacerbates Licensing Contact: Chris Kornak, 240– Name of Committee: Center for Scientific Endotoxemia and Septic Peritonitis 627–3705, chris.kornak@nih.gov. Review Special Emphasis Panel; Member Description of Technology: The innate Collaborative Research Opportunity: Conflict: Emerging Technologies in immune system is the first line of host The National Institute of Allergy and Neuroscience. defense against invading pathogens. Infectious Diseases is seeking statements Date: March 24, 2017. Lipopolysaccharides (LPS), present in of capability or interest from parties Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant gram-negative bacteria membranes, interested in collaborative research to applications. cause strong immune responses further co-develop CD300b antagonists. Place: National Institutes of Health, 6701 following detection by the Toll-like For collaboration opportunities, please Rockledge Drive, Bethesda, MD 20892, receptor 4 (TLR4) on immune cells. This contact Chris Kornak, 240–627–3705, (Virtual Meeting). detection results in the release of pro- chris.kornak@nih.gov. Contact Person: Sharon S Low, Ph.D., inflammatory cytokines, such as tumor Dated: February 16, 2017. Scientific Review Officer, Center for necrosis factor alpha, interleukin-6, and Scientific Review, National Institutes of Suzanne Frisbie, interferon gamma, to assist with Health, 6701 Rockledge Drive, Room 5104, Deputy Director, Technology Transfer and MSC 5104, Bethesda, MD 20892–5104, 301– clearance of the infectious insult. In Intellectual Property Office, National Institute 237–1487, lowss@csr.nih.gov. parallel, interleukin-10 (IL–10), an anti- of Allergy and Infectious Diseases. (Catalogue of Federal Domestic Assistance inflammatory cytokine, is induced to [FR Doc. 2017–03452 Filed 2–22–17; 8:45 am] Program Nos. 93.306, Comparative Medicine; limit the immune response. This is BILLING CODE 4140–01–P 93.333, Clinical Research, 93.306, 93.333, because unchecked immune activation 93.337, 93.393–93.396, 93.837–93.844, leads to a more severe 93.846–93.878, 93.892, 93.893, National immunopathology, such as septic shock DEPARTMENT OF HEALTH AND Institutes of Health, HHS) and subsequently death. Current HUMAN SERVICES Dated: February 17, 2017. therapies to treat sepsis are ineffective, Anna Snouffer, and clinical trials based on National Institutes of Health Deputy Director, Office of Federal Advisory neutralization of specific inflammatory Committee Policy. cytokines have failed. National Institute of Allergy and [FR Doc. 2017–03528 Filed 2–22–17; 8:45 am] The inventors, listed below, have Infectious Diseases; Notice of Closed discovered that CD300b is a LPS Meeting BILLING CODE 4140–01–P binding receptor. This interaction Pursuant to section 10(d) of the results in a reduced IL–10 production, Federal Advisory Committee Act, as DEPARTMENT OF HEALTH AND leading to an amplification of lethal amended (5 U.S.C. App.), notice is HUMAN SERVICES inflammation. In vitro, anti-CD300b hereby given of the following meeting. antibodies block LPS binding to The meeting will be closed to the National Institutes of Health CD300b, stopping association with public in accordance with the TLR4 and CD14 and increases IL–10 Government-Owned Inventions; provisions set forth in sections levels. In vivo, administration of anti- Availability for Licensing 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., CD300b antibodies protects animals as amended. The grant applications and AGENCY: National Institutes of Health, from septic shock, due to a reduce level the discussions could disclose HHS. of pro-inflammatory cytokines but confidential trade secrets or commercial subsequent increase in the anti- ACTION: Notice. property such as patentable material, inflammatory cytokine, IL–10. This technology is available for and personal information concerning SUMMARY: The invention listed below is individuals associated with the grant owned by an agency of the U.S. licensing for commercial development in accordance with 35 U.S.C. 209 and 37 applications, the disclosure of which Government and is available for would constitute a clearly unwarranted licensing to achieve expeditious CFR part 404, as well as for further development and evaluation under a invasion of personal privacy. commercialization of results of federally-funded research and research collaboration. Name of Committee: National Institute of development. Foreign patent Potential Commercial Applications: Allergy and Infectious Diseases Special As a means of treating endotoxemia and Emphasis Panel, Elucidation of Mechanisms applications are filed on selected of Radiation-Induced Endovascular Injury inventions to extend market coverage septic peritonitis. and Development of Treatments/Mitigators for companies and may also be available Competitive Advantages: No current for Radiation-Induced Endothelial Cell and for licensing. therapeutics are available to treat septic Vascular Dysfunction (U01). FOR FURTHER INFORMATION CONTACT: shock. Date: March 16–17, 2017. Licensing information and copies of the Development Stage: Pre-clinical. Time: 10:00 a.m. to 5:00 p.m. rmajette on DSK2TPTVN1PROD with NOTICES patent applications listed below may be Inventors: Agenda: To review and evaluate grant obtained by communicating with the John E. Coligan, NIAID, NIH applications. Oliver H. Voss, NIAID, NIH Place: National Institutes of Health, 5601 indicated licensing contact at the Fishers Lane, Rockville, MD 20892, Technology Transfer and Intellectual Konrad Krzewski, NIAID, NIH (Telephone Conference Call). Property Office, National Institute of Publications: Voss, Oliver H., et al. Contact Person: Zhuqing (Charlie) Li, Allergy and Infectious Diseases, 5601 ‘‘Lipopolysaccharide-induced CD300b Ph.D., Scientific Review Officer, Scientific Fishers Lane, Rockville, MD, 20852; tel. receptor binding to toll-like receptor 4 Review Program, Division of Extramural VerDate Sep<11>2014 14:10 Feb 22, 2017 Jkt 241001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 E:\FR\FM\23FEN1.SGM 23FEN1


Document Created: 2017-02-23 02:10:49
Document Modified: 2017-02-23 02:10:49
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesMarch 8, 2017.
FR Citation82 FR 11474 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR